Feuerstein comments hit Ampio in early trading

|About: Ampio Pharmaceuticals, Inc. (AMPE)|By:, SA News Editor

Ampio Pharmaceuticals (AMPE) is trading 6.6% lower premarket.

Likely behind the move is TheStreet's Adam Feuerstein who, in a response to an article by SA contributor Brian Wilson, says the company "slipped in" new disclosures regarding Optina in the prospectus for its most recent financing.

According to Feuerstein, the company's disclosure that "the FDA has previously indicated that a Phase 3 trial may be necessary following the current trial" is quite a change of pace from the language present in AMPE's March 10-Q.

"The FDA has never approved a drug for DME based on a 12-week clinical trial," Feuerstein says.